Compare KTB & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTB | GH |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 13.3B |
| IPO Year | 2018 | 2018 |
| Metric | KTB | GH |
|---|---|---|
| Price | $66.52 | $84.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 20 |
| Target Price | $99.67 | ★ $117.80 |
| AVG Volume (30 Days) | 931.9K | ★ 1.5M |
| Earning Date | 03-03-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $2,097,839,000.00 | $982,021,000.00 |
| Revenue This Year | $10.39 | $33.40 |
| Revenue Next Year | $3.91 | $28.32 |
| P/E Ratio | $16.61 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $50.00 | $36.36 |
| 52 Week High | $87.00 | $120.74 |
| Indicator | KTB | GH |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 37.50 |
| Support Level | $61.85 | $82.26 |
| Resistance Level | $71.66 | $90.28 |
| Average True Range (ATR) | 2.57 | 3.70 |
| MACD | -0.47 | 0.37 |
| Stochastic Oscillator | 17.27 | 19.96 |
Kontoor Brands Inc is a lifestyle apparel company. It designs, manufactures, procures, sells, and licenses apparel, footwear, and accessories, mainly under the brand names Wrangler, Lee, Helly Hansen, and a few other brands. The company also licenses the use of its brands in certain regions. Its products are sold through wholesale and direct-to-consumer channels in the United States (its key revenue-generating market) and internationally, mainly in Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Non-U.S. Americas regions. The company's three reportable segments are Wrangler, Lee, and Helly Hansen. The majority of its revenue is generated from the Wrangler segment, which offers denim, apparel, footwear, and accessories through Wrangler and various sub-brands.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.